Ultragenyx (RARE) CFO sale reported, 88,935 shares still held

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reported a stock sale. On 02/02/2026, he sold 3,061 shares of Ultragenyx common stock at a price of $23.56 per share.

After this transaction, he beneficially owns 88,935 shares of common stock. This figure includes previously reported shares underlying restricted stock units (RSUs) that were granted to him and are still subject to vesting conditions.

Insider Trade Summary

Net Seller: 3,061 shares ($72,117)

Net Sell 1 txn

Insider Horn Howard

Role Chief Financial Officer

Sold 3,061 shs ($72K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,061	$23.56	$72K

Holdings After Transaction: Common Stock — 88,935 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Howard

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S		3,061	D	$23.56	88,935(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

	/s/ Karah Parschauer, attorney-in-fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Ultragenyx (RARE) report for CFO Howard Horn?

Ultragenyx reported that Chief Financial Officer Howard Horn sold 3,061 shares of common stock. The sale occurred on February 2, 2026 at a price of $23.56 per share, according to the insider ownership filing for this officer.

How many Ultragenyx (RARE) shares does CFO Howard Horn hold after the sale?

After the reported sale, CFO Howard Horn beneficially owns 88,935 Ultragenyx common shares. This total includes shares underlying previously reported restricted stock units (RSUs) that were granted to him and remain subject to vesting conditions before fully becoming regular common stock.

At what price were the Ultragenyx (RARE) shares sold in this insider trade?

The reported insider sale by Ultragenyx CFO Howard Horn was executed at $23.56 per share. He sold 3,061 shares of common stock at this price on February 2, 2026, as disclosed in the non-derivative securities transaction table for this filing.

Does Howard Horn’s Ultragenyx (RARE) share count include RSUs?

Yes. The 88,935 Ultragenyx shares beneficially owned by CFO Howard Horn include previously reported shares underlying restricted stock units. These RSUs were granted to him and are subject to specific vesting conditions before they become fully unrestricted common shares.

What type of security was involved in the Ultragenyx (RARE) insider transaction?

The insider transaction involved Ultragenyx common stock, categorized as a non-derivative security. CFO Howard Horn sold 3,061 common shares and continued to hold 88,935 common shares, including those represented by restricted stock units subject to vesting requirements.